Crescent Biopharma clinical trials
Crescent Biopharma is the lead sponsor of 3 current clinical trials in our USA, Ireland, UK, France, Spain, Italy, South Korea, Australia and EU (CTIS) registers. 2 are recruiting patients now. All registered phases are Phase 1/2. The drugs named most often in its trials are Capecitabine, Carboplatin and Cisplatin. The most-studied condition is Locally Advanced / Metastatic Solid Tumors.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Crescent Biopharma
2 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497 · Locally Advanced / Metastatic Solid Tumors
|
Phase 1/2 | Recruiting | 2026-02 | Ireland, UK, USA, France, Spain, Italy, South Korea, Australia |
|
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07909031 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)
|
Phase 1/2 | Recruiting | 2026-10 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Crescent Biopharma in the EU trials register (CTIS)
1 trial · 1 in IrelandAuthorised or ongoing trials in the EU Clinical Trials Information System with Crescent Biopharma as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.
2025-523590-42-00 · Neoplasms
|
Phase 1 | Ongoing | Ireland + 4 more |
Drugs in Crescent Biopharma trials
9 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Crescent Biopharma trials
5 conditionsBy trial register
A trial with sites in more than one country appears in each of those registers.
Questions about Crescent Biopharma trials
How many clinical trials does Crescent Biopharma sponsor?
Crescent Biopharma is the lead sponsor of 2 current trials on ClinicalTrials.gov in our USA, Ireland, UK, France, Spain, Italy, South Korea and Australia registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 3 November 2026. Completed and withdrawn studies are not counted.
Are Crescent Biopharma trials recruiting?
Yes. 2 of its 2 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Crescent Biopharma testing?
Its current trials name 9 drugs and biologicals as interventions. The most frequent are Capecitabine (1), Carboplatin (1), Cisplatin (1), Folfox (1) and Gemcitabin (1). The number in brackets is how many of its trials name each drug.
Does Crescent Biopharma have clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 3 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.